About S-geranylgeranyl-glutathione receptor P2RY8
S-geranylgeranyl-glutathione receptor P2RY8 (P2RY8) is a protein
from Homo sapiens identified by UniProt accession
Q86VZ1, 359 residues long.
MolForge cross-references it against 0 known binders and
97 disease associations.
Target properties
| Protein name | S-geranylgeranyl-glutathione receptor P2RY8 |
| UniProt accession | Q86VZ1 |
| Gene | P2RY8 |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (97)
Diseases linked to this target (Open Targets).
- Burkitts lymphoma · score 0.47
- diffuse large B-cell lymphoma · score 0.45
- lymphoid neoplasm · score 0.41
- non-Hodgkins lymphoma · score 0.37
- kidney neoplasm · score 0.37
- lung carcinoma · score 0.37
- skin carcinoma · score 0.37
- Endometrial Endometrioid Adenocarcinoma · score 0.37
- Gastric Diffuse Large B-Cell Lymphoma · score 0.37
- Small Intestinal Diffuse Large B-Cell Lymphoma · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86VZ1-F1 | alphafold | PREDICTED | 84.27 | — |
Amino-acid sequence (359 residues)
MQVPNSTGPD NATLQMLRNP AIAVALPVVY SLVAAVSIPG NLFSLWVLCR RMGPRSPSVI FMINLSVTDL MLASVLPFQI YYHCNRHHWV FGVLLCNVVT VAFYANMYSS ILTMTCISVE RFLGVLYPLS SKRWRRRRYA VAACAGTWLL LLTALSPLAR TDLTYPVHAL GIITCFDVLK WTMLPSVAMW AVFLFTIFIL LFLIPFVITV ACYTATILKL LRTEEAHGRE QRRRAVGLAA VVLLAFVTCF APNNFVLLAH IVSRLFYGKS YYHVYKLTLC LSCLNNCLDP FVYYFASREF QLRLREYLGC RRVPRDTLDT RRESLFSART TSVRSEAGAH PEGMEGATRP GLQRQESVF
Explore S-geranylgeranyl-glutathione receptor P2RY8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets